Back to Search
Start Over
Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.
- Source :
-
Revista peruana de medicina experimental y salud publica [Rev Peru Med Exp Salud Publica] 2024 May 27; Vol. 41 (1), pp. 7-18. - Publication Year :
- 2024
-
Abstract
- Objective.: Motivation for the study. Treatment options for HER2-positive breast cancer were evaluated, focusing on the efficacy and safety of trastuzumab-emtansine (T-DM1) compared to other anti-HER2 therapies. Main findings. Trastuzumab-deruxtecan (T-DXd) and PyroCap emerged as promising alternatives, showing substantial improvements in progression-free survival for locally advanced or metastatic breast cancer. T-DM1 showed superior efficacy to the other treatments. Implications. Our findings could inform healthcare decision-making processes to optimize strategies for HER2-positive breast cancer, and potentially improve health outcomes and quality of life. We aimed to study the efficacy and safety of trastuzumab-emtansine (T-DM1) versus other anti-HER2 therapies in HER2+ breast cancer (BC).<br />Materials and Methods.: We performed a network meta-analysis (NMA) of randomized controlled trials (RCTs). Our study focused on patients undergoing treatment for unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC), which included regimens involving trastuzumab and taxanes. Additionally, we considered cases within the first 6 months of treatment for HER2+ early breast cancer (EBC).<br />Results.: A total of 23 RCTs and 41 reports were included in our analysis. LABC and mBC showed no statistically significant difference in any of the comparisons of T-DM1 versus the other anti-HER2+ therapies. When assessing progression-free survival (PFS), trastuzumab-deruxtecan (T-DXd) and PyroCap demonstrated greater efficacy compared to other treatments (Hazard Ratio [HR]: 3.57; 95% confidence interval [CI]: 2.75-4.63 and HR: 1.82; 95% CI: 1.35-2.44; respectively), while T-DM1 alone exhibited superior effectiveness compared to LapCap (HR: 0.65; 95% CI: 0.55-0.77), TrasCap (HR: 0.65; 95% CI: 0.46-0.91), LapCapCitu (HR: 0.60; 95% CI: 0.33-1.10), Nera (HR: 0.55; 95% CI: 0.39-0.77), and Cap (HR: 0.37; 95% CI: 0.28-0.49).<br />Conclusions.: NMA allows a ranking based on the comparative efficacy and safety among the interventions available. Although superior to other schemes, T-DM1 showed a lower efficacy performance in PFS and overall response rate and a trend towards worse overall survival than T-DXd.
- Subjects :
- Humans
Female
Trastuzumab therapeutic use
Network Meta-Analysis
Randomized Controlled Trials as Topic
Neoplasm Metastasis
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Maytansine analogs & derivatives
Maytansine therapeutic use
Breast Neoplasms drug therapy
Breast Neoplasms pathology
Ado-Trastuzumab Emtansine therapeutic use
Receptor, ErbB-2
Antineoplastic Agents, Immunological therapeutic use
Subjects
Details
- Language :
- Spanish; Castilian; English
- ISSN :
- 1726-4642
- Volume :
- 41
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Revista peruana de medicina experimental y salud publica
- Publication Type :
- Academic Journal
- Accession number :
- 38808848
- Full Text :
- https://doi.org/10.17843/rpmesp.2024.411.13351